Cancer tumours halt immune response
Posted on 04/03/2013
Tumours deliberately create conditions that inhibit body’s best immune response so cancer can progress
New research in the Journal of Clinical Investigation reveals that tumours in melanoma patients deliberately create conditions that knock out the body’s ‘premier’ immune defence and instead attract a weaker immune response unable to kill off the tumour’s cancerous cells.
The study also highlights a potential antibody biomarker that could help predict prognosis and identify which patients are most likely to respond to specific treatments.
The research, led by Dr Sophia Karagiannis and Professor Frank Nestle at King’s College London, UK, was funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London.
Karagiannis and colleagues have previously shown that, in patients with melanoma, antibodies are produced that can attack tumour cells. Despite this, the patient’s immune system is often ineffective in preventing the cancer from progressing.
The body’s B cells (part of the immune system) produce a total of 5 different antibody classes. The most common, IgG, comprises 4 types (or subclasses) of which the researchers have shown that IgG1 subclass antibodies are the most effective at activating immune cells, while antibodies of the IgG4 subclass are thought to be the least efficient.
In this new research, the authors analysed tumour tissue and blood donated by 80 patients from the melanoma clinic of St John’s Institute of Dermatology at Guy’s and St Thomas’, as well as tissue and blood from healthy volunteers.
By analysing the lesions found in melanoma, the authors show that melanoma tumours not only create conditions that attract IgG4, the weakest possible response, but also that IgG4 antibodies interfere with the action of any IgG1 antibodies circulating. 'We were able to mimic the conditions created by melanoma tumours and showed that B cells can be polarised to produce IgG4 antibodies in the presence of cancer cells,' says Dr Karagiannis. In the presence of healthy cells, the body’s immune response functions normally, and IgG1 are the main antibodies circulating.
To better understand the functional implications of IgG4 subclass antibodies in cancer, the authors engineered these two antibodies (IgG1, IgG4) against a tumour antigen and demonstrated that unlike IgG1, the IgG4 antibody was ineffective in triggering immune cells to kill cancer cells. Importantly, IgG4 also blocked the tumour cell killing actions of IgG1, thus preventing this antibody from activating immune cells to destroy tumours.
Additionally, using samples from 33 patients, the authors found that patients with higher IgG4 levels in their blood are more likely to have a less favourable prognosis compared to those whose blood levels of IgG4 are closer to normal levels. This suggests that IgG4 may help assist in predicting disease progression.
'This work bears important implications for future therapies since not only are IgG4 antibodies ineffective in activating immune cells to kill tumours but they also work by blocking antibodies from killing tumour cells', says Dr Karagiannis. 'The latter means that IgG4 not only prevents the patient’s more powerful antibodies from eradicating cancer, but could also explain why treatments may be hindered by those native IgG4 antibodies found in patients, making therapeutic antibodies less effective.'
'Now, with the help of our NIHR Biomedical Research Centre, more work needs to be done on developing IgG4 as a potential clinical and prognostic biomarker which can improve patient care by informing clinical decisions and helping to identify patients most likely to respond to treatments,' concludes Professor Nestle. Therefore, these findings are expected to inform the design and help improve the potency and efficacy of future therapies for cancer. 'This study can also inform the rational design of novel strategies to counteract IgG4 actions.'
The authors are now broadening the study by examining larger groups of patients. The team is analysing blood and sera from patients with melanoma and from patients with other cancers to determine whether the presence of IgG4 could inform patient outcomes or predict responses to therapy. They are also analysing the mechanisms of IgG4 blockade of new and existing therapeutic antibody candidates, and developing new antibody candidates which may be less prone to IgG4 blockade.
To interview Dr Sophia Karagiannis, please contact Emma Reynolds, PR Manager (Health), King’s College London, on 0207 848 4334 or email@example.com.
Notes to editors
The study additionally benefited from support from Cancer Research UK (CR UK) and CR UK New Agents Committee; and by the CR UK//NIHR Experimental Cancer Medicine Centre.
For further information about King's visit our 'King's in Brief' page.
NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London
The NIHR Guy’s and St Thomas’ Biomedical Research Centre focuses on translational research through four ‘research clusters’: experimental medicine and therapeutics; biomarkers, co-diagnostics and imaging; population sciences; the school of translational and experimental medicine. Research within these clusters is based around eight research themes: cancer; cardiovascular disease; cutaneous medicine; environmental and respiratory health; imaging and bio-engineering; infection & immunity; translational genetics; and transplantation. Our aim is to take advances in basic medical research out of the laboratory and into the clinical setting to benefit patients at the earliest opportunity. Access to the uniquely diverse patient population of London and the south east enables us to drive forward research into a wide range of diseases and medical conditions.
About the National Institute for Health Research
The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world.